No difference between Macugen and triamcinolone

Article

A study, which was halted before the completion of enrolment, failed to demonstrate any difference in the visual outcomes or safety concerns in patients with neovascularization secondary to age-related macular degeneration (AMD) who were treated with photodynamic therapy (PDT) in combination with either intravitreal injections of Macugen (pegaptanib sodium) or triamcinolone

A study, which was halted before the completion of enrolment, failed to demonstrate any difference in the visual outcomes or safety concerns in patients with neovascularization secondary to age-related macular degeneration (AMD) who were treated with photodynamic therapy (PDT) in combination with either intravitreal injections of Macugen (pegaptanib sodium) or triamcinolone, according to a presentation at this year's meeting of the Association for Research in Vision and Ophthalmology (ARVO).

Peter Kaiser from the Cole Eye Institute, Ohio, USA presented the findings of the study in which patients were randomized to receive either PDT plus pegaptanib sodium 0.3 mg (n=38), PDT plus triamcinolone 1 mg (n=32) or triamcinolone 4 mg (n=41). The study was halted early, with only 111 patients of the intended 339 taking part.

After six-months follow-up there were no significant differences between groups in terms of the primary endpoint - a loss of 15 letters on the visual acuity test. All percentages were much lower than had been expected (PDT plus pegaptanib sodium 73.7%; PDT plus triamcinolone 81.3%; triamcinolone 73.2%). There was also no significant difference in the area of neovascularization between the two steroid groups and the pegaptanib sodium group. All groups demonstrated a significant reduction in central retinal thickness.

In terms of safety, 14% of patients receiving triamcinolone had significant spikes in their intraocular pressure, although it did not result in any acute losses in visual acuity. Overall the safety was considered to be reasonably good in each group.

Despite the early termination of enrolment, patients will continue treatment until the 12-month endpoint.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.